ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

SOUTH SAN FRANCISCO and SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...
C&EN

Base editing in human embryos fixes some mutations and creates others

The work proves that embryo editing is far from a clinical reality. But the experiment has sparked controversy nonetheless ...

COPA mutations reveal alternative trigger for small intestine tumors

A signaling system known as the Wnt pathway plays a central role in how cells in the intestine grow, divide and renew ...

Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 10:40 AM EDTCompany ParticipantsAllan Reine - ...
GameSpot

All Grounded 2 Mutations And How To Unlock Them

GameSpot may receive revenue from affiliate and advertising partnerships for sharing this content and from purchases through links. The outdoors feels more dangerous than ever in Grounded 2, and many ...

The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight

The EGFR-NSCLC pipeline possesses some drugs in late-stage development to be approved in the near future. The emerging ...
The New England Journal of Medicine

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

Sunvozertinib received accelerated approval for use in later lines of therapy for patients with advanced non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...
Morningstar

Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small ...

SHANGHAI, May 29, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, today announced the results from ...
Medical Xpress

Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer

The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR ...
manilatimes

Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small ...

ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20ins WU-KONG28 is the first global randomized ...
National Institute for Health and Care Excellence

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...
National Institute for Health and Care Excellence

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...